Aim Immunotech Inc. (AIM)
XASE:AIM
Want to see AIM full AI Analyst Report?
Top Page
AIM ImmunoTech
(NYSE MKT:AIM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.47
▼(-62.24% Downside)
Action:ReiteratedDate:04/22/26
The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn with balance-sheet pressure) and a strong technical downtrend (price below key moving averages with negative momentum). The recent financing modestly improves near-term funding flexibility, but valuation support is limited given negative earnings and no dividend yield data.
Positive Factors
Focused immunomodulator platform
AIM’s strategic focus on a single immunomodulatory platform (Ampligen) creates a durable R&D franchise: a platform can be applied across viral and oncology indications, supports licensing or partnership deals, and concentrates scientific expertise, enabling longer-term value capture if trials succeed.
Negative Factors
Declining, minimal revenue
Revenue trends show persistent lack of commercial traction, leaving operations almost entirely funded by financing rather than product income. Over a multi-month horizon this structural lack of earned revenue heightens funding dependency and limits reinvestment capacity for trial advancement.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused immunomodulator platform
AIM’s strategic focus on a single immunomodulatory platform (Ampligen) creates a durable R&D franchise: a platform can be applied across viral and oncology indications, supports licensing or partnership deals, and concentrates scientific expertise, enabling longer-term value capture if trials succeed.
Read all positive factors
AIM ImmunoTech (AIM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.27M
Dividend YieldN/A
Average Volume (3M)6.65M
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-48.24%
EPS Growth62.05%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.39
Shares Outstanding8,147,782
10 Day Avg. Volume365,407
30 Day Avg. Volume6,652,625
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.17
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue65.33
Enterprise Value/Gross Profit-41.97
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$10.00Price Target Upside700.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.33
Revenue Forecast (FY)$100.00K
AIM ImmunoTech Business Overview & Revenue Model
Company Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (ri...
How the Company Makes Money
AIM ImmunoTech’s monetization is primarily tied to advancing and potentially commercializing its drug candidates—most notably Ampligen (rintatolimod). In general, for a clinical-stage biotech like AIM, revenue (when present) typically comes from o...
AIM ImmunoTech Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.Positive Updates
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Negative Updates
Low Cash Reserves
As of December 31, 2024, AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities, highlighting potential financial constraints.
Read all updates
Q4-2024 Updates
Positive
Negative
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Read all positive updates
Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.AIM ImmunoTech Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.00K | 170.00K | 202.00K | 141.00K | 135.00K |
| Gross Profit | -250.00K | 139.00K | 160.00K | 565.00K | -715.00K |
| EBITDA | -10.32M | -16.49M | -28.72M | -19.87M | -18.29M |
| Net Income | -13.96M | -17.32M | -28.96M | -19.45M | -19.13M |
Balance Sheet | |||||
| Total Assets | 5.78M | 8.61M | 19.38M | 40.49M | 57.70M |
| Cash, Cash Equivalents and Short-Term Investments | 993.00K | 3.98M | 13.07M | 34.19M | 48.27M |
| Total Debt | 4.90M | 2.94M | 718.00K | 837.00K | 149.00K |
| Total Liabilities | 15.56M | 9.93M | 9.15M | 2.02M | 820.00K |
| Stockholders Equity | -9.78M | -1.32M | 10.23M | 38.47M | 56.88M |
Cash Flow | |||||
| Free Cash Flow | -10.96M | -14.91M | -21.85M | -16.38M | -14.60M |
| Operating Cash Flow | -10.96M | -14.89M | -21.27M | -16.11M | -13.96M |
| Investing Cash Flow | 1.85M | 4.71M | -832.00K | 10.99M | -631.00K |
| Financing Cash Flow | 10.39M | 6.44M | 485.00K | 80.00K | 8.19M |
AIM ImmunoTech Technical Analysis
Negative
1.25
Price Trends
0.80
Negative
1.06
Negative
2.32
Negative
Market Momentum
-0.08
Negative
38.97
Neutral
36.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.80, and below the 200-day MA of 2.32, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 38.97 is Neutral, neither overbought nor oversold. The STOCH value of 36.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.
AIM ImmunoTech Risk Analysis
AIM ImmunoTech disclosed 33 risk factors in its most recent earnings report. AIM ImmunoTech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AIM ImmunoTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $28.71M | -0.14 | -380.13% | ― | ― | 54.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $7.05M | -0.55 | -257.81% | ― | ― | 82.64% | |
43 Neutral | $4.27M | -0.13 | 212.59% | ― | -48.24% | 62.05% | |
43 Neutral | $8.58M | -0.15 | -356.99% | ― | ― | -108.12% |
* Healthcare Sector Average
AIM
AIM ImmunoTech
0.52
-7.35
-93.42%
GTBP
GT Biopharma
0.31
-2.14
-87.43%
PMCB
PharmaCyte Biotech
0.72
-0.45
-38.29%
PCSA
Processa Pharmaceuticals
2.70
-3.55
-56.80%
APLM
Apollomics
13.00
6.55
101.55%
AIM ImmunoTech Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity
Neutral
Apr 10, 2026
On April 10, 2026, AIM ImmunoTech Inc. amended its existing Equity Distribution Agreement with Maxim Group LLC, which had previously capped at-the-market sales of its common stock at $3 million. The amendment removes that cap, allowing the company...
Business Operations and StrategyPrivate Placements and Financing
AIM ImmunoTech Completes Series G Preferred Rights Offering
Positive
Mar 6, 2026
On March 4, 2026, AIM ImmunoTech created a new Series G Convertible Preferred Stock, authorizing 12,000 shares with a $1,000 stated value each, initially convertible into common stock at $1.00 per share and subject to ownership caps between 4.99% ...
Business Operations and Strategy
AIM ImmunoTech Provides Interim DURIPANC Clinical Progress Update
Neutral
Feb 5, 2026
On February 5, 2026, AIM ImmunoTech furnished investors with a February 2026 corporate presentation, a year-end interim clinical progress update on its DURIPANC program, and a related press release, providing a consolidated view of its current dev...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.